METMetLife
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 18.8 vs a 10.3 median over 37 quarters (+83% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MET's price assumes
MetLife trades at 18.8× earnings against 14.0× for the median Insurance - Life name, more expensive than its own group.
Trailing P/E · Insurance - Life median 14.0 · 1.35× the median: the market pays up for this one
- Price / sales
- 0.69
Price / sales · as of 2026-Q2
- Price / book
- 1.99
Price / book · as of 2026-Q2
- EV / sales
- 0.53
EV / sales
Details›
- Price / bookas of 2026-Q2
- 1.99
- EV / salesas of 2026-Q2
- 0.53
- Financial Services median P/E625 names
- 12.1
- Insurance - Life median P/E15 names
- 14.0
- Market capitalisation
- $55.1B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $36.64 |
| Its own P/E history, median | $53.76 |
| Its own P/E history, upper quartile | $79.36 |
| 52-week range | $67.19 – $100.00 |
| Today | $98.31 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Insurance, Life
The closest names by size in the same industry